Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

Dow Jones01-17

1632 GMT - Sanofi might need deals to offset disappointing data for some of the drugs in its pipeline that stoked investors' concerns about its research-and-development productivity, UBS analysts say in a research note. "Meaningful [mergers & acquisitions] may be the only realistic solution, which brings significant uncertainty and risks, and also reduces the possibility of systematic buybacks to boost [earnings-per-share] growth," the analysts say. Disappointing data for multiple sclerosis drug candidate tolebrutinib and a hit from new U.S. pediatric vaccination schedules prompt UBS to cut its midterm estimates for the French drugmaker by about 8%. UBS also lowers its recommendation on the stock to neutral from buy, while trimming its target price to 88 euros from 105 euros. Shares fall 1.3% to 80.55 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 11:32 ET (16:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604990912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604990912","market":"sh","top_or_hot":-1,"title":"Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1632 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> might need deals to offset disappointing data for some of the drugs in its pipeline that stoked investors' concerns about its research-and-development productivity, UBS analysts say in a research note. \"Meaningful [mergers &amp; acquisitions] may be the only realistic solution, which brings significant uncertainty and risks, and also reduces the possibility of systematic buybacks to boost [earnings-per-share] growth,\" the analysts say. Disappointing data for multiple sclerosis drug candidate tolebrutinib and a hit from new U.S. pediatric vaccination schedules prompt UBS to cut its midterm estimates for the French drugmaker by about 8%. UBS also lowers its recommendation on the stock to neutral from buy, while trimming its target price to 88 euros from 105 euros. Shares fall 1.3% to 80.55 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 11:32 ET (16:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-17 00:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1632 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> might need deals to offset disappointing data for some of the drugs in its pipeline that stoked investors' concerns about its research-and-development productivity, UBS analysts say in a research note. \"Meaningful [mergers &amp; acquisitions] may be the only realistic solution, which brings significant uncertainty and risks, and also reduces the possibility of systematic buybacks to boost [earnings-per-share] growth,\" the analysts say. Disappointing data for multiple sclerosis drug candidate tolebrutinib and a hit from new U.S. pediatric vaccination schedules prompt UBS to cut its midterm estimates for the French drugmaker by about 8%. UBS also lowers its recommendation on the stock to neutral from buy, while trimming its target price to 88 euros from 105 euros. Shares fall 1.3% to 80.55 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 11:32 ET (16:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2604990912","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604990912","pubTimestamp":1768581120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1632 GMT - Sanofi might need deals to offset disappointing data for some of the drugs in its pipeline that stoked investors' concerns about its research-and-development productivity, UBS analysts say in a research note. \"Meaningful [mergers & acquisitions] may be the only realistic solution, which brings significant uncertainty and risks, and also reduces the possibility of systematic buybacks to boost [earnings-per-share] growth,\" the analysts say. Disappointing data for multiple sclerosis drug candidate tolebrutinib and a hit from new U.S. pediatric vaccination schedules prompt UBS to cut its midterm estimates for the French drugmaker by about 8%. UBS also lowers its recommendation on the stock to neutral from buy, while trimming its target price to 88 euros from 105 euros. Shares fall 1.3% to 80.55 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药","SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"赛诺菲需要交易来抵消管道的失望——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"1632 GMT - Sanofi might need deals to offset disappointing data for some of the drugs in its pipeline that stoked investors' concerns about its research-and-development productivity, UBS analysts say in a research note. \"Meaningful [mergers & acquisitions] may be the only realistic solution, which brings significant uncertainty and risks, and also reduces the possibility of systematic buybacks to boost [earnings-per-share] growth,\" the analysts say. Disappointing data for multiple sclerosis drug candidate tolebrutinib and a hit from new U.S. pediatric vaccination schedules prompt UBS to cut its midterm estimates for the French drugmaker by about 8%. UBS also lowers its recommendation on the stock to neutral from buy, while trimming its target price to 88 euros from 105 euros. Shares fall 1.3% to 80.55 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 11:32 ET (16:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604990912","isCrawlerRequest":true}